Search JIC Articles:
The Official Journal of the International Andreas Gruentzig Society
Saturday, September 6, 2008


text size: A A A
manuscripts: submit | review
Contemporary Prevention, Management and Treatment of Stroke — Who Will Treat Acute Stroke in 2010 and How Will It Be Treated? <i>Setting the Stage</i>
IAGS (International Andreas Gruentzig Society) Proceedings:
Contemporary Prevention, Management and Treatment of Stroke — Who Will Treat Acute Stroke in 2010 and How Will It Be Treated? Setting the Stage

- David Holmes, MD, Moderator


       We’re going to move on to the second session entitled: Contemporary Prevention, Management and Treatment of Stroke — Who Will Treat Acute Stroke in 2010 and How Will It Be Treated?

       The data on this first slide (Figure 1) show the magnitude of the problem of stroke. These are
Figure 1
2001 data from the World Health Organization. At that time, the World Health Organization identified that there were 20 million strokes worldwide; 5.5 million of those were fatal. On the east side of the Atlantic, in Europe, there are 650,000 deaths due to stroke every year. On the west side of the Atlantic, there were about 750,000 strokes per year, with an enormous number of deaths related to stroke. Stroke is the third leading cause of death behind diseases of the heart and cancer, and it’s the first cause of serious long-term disability. The final piece of information I want to mention is that stroke costs society about 3% of the total.
       What do we know about the changing incidence of stroke? These data (Figure 2) come from the county in which I live in Minnesota. It shows the stroke rate for a population of 100,000. When you live in a small county with a small population, it is possible to follow every single person. Thus these data, in terms of the stroke incidence rate, are very accurate. It could be that
Figure 3
the stroke
Figure 2
rates are different in Italy or in Germany, but these are data from longitudinal follow up in this patient population, looking at the age-adjusted incidence rate for a population of 100,000.
       You can also see in Figure 2 that there was a progressive decline in stroke from 1955 to 1975. Recall that death rates from coronary artery disease have continued to fall. This is not true for stroke, however. Stroke, at least in the United States, stopped declining in 1975 and, if anything, has increased. It is not continuing to fall for reasons that are not clear, other than the fact that everybody is getting older. So we’re going to have a chance to see a lot of strokes in the future as the patient population increases.
       What are the mechanisms of stroke? Nick Hopkins is going to talk about some of these issues. Figure 3 shows more data that again are from a couple of years ago from CHES looking at the different etiology of stroke. We can see the large artery
Figure 4
atherosclerosis 20%, the lacune infarcts 25%, cardio-embolic 20%, cryptogenic 30%. How do we treat cryptogenic stroke? And then there’s another small group, the 5% of patients whom we don’t have a clue about. So these are going to be issues for us to talk about as we try to design strategies for stroke prevention and treatment.
       The final piece of information following our discussion about the mechanisms and incidence of stroke and the fact that they haven’t changed very much, is the fact that the mechanism of stroke has a substantial implication for subsequent survival. Stroke’s subtype is seen in Figure 4. When we look at these curves for strokes in 2000, we can see that in those patients in whom there was a cardio-embolic stroke, the survival at 5 years is abysmal, at 20%. If you were to ask about the group of patients who have stroke related to atherosclerosis, it’s not all that bad. It’s not great, but it’s not all that bad. Lacune strokes have about an 80% survival rate. Thus stroke outcome will be very dependent upon the mechanism of stroke.
       Now with that background in place, I’ll turn the microphone over to Nick Hopkins.

 

 

 

 

 

 

 

 


The Journal of Invasive Cardiology - ISSN: 1042-3931 - Volume 19 - Issue 3 - March 2007 - Pages: E84 - E84



Novel Approaches to Managing Bradycardia during Coronary Rheolytic Thrombectomy

Special Supplement to the Journal of Invasive Cardiology


This special supplement was made possible through a grant from Possis Medical, Inc.
CLINICAL EXPERIENCE WITH A NEW HYBRID CORONARY WIRE

On Demand Web Archive
Non-Accredited


This activity is supported by an educational grant from Terumo Medical Corporation.
Pharmacoinvasive Management of Acute Coronary Syndrome: Incorporating the 2007 ACC/AHA Guidelines

Complimentary Accredited CME Program

This activity is supported by an educational grant from Sanofi-Aventis.
Varicose Veins: Causes, Symptoms, Diagnosis and Treatment of Chronic Venous Insufficiency

A Complimentary Accredited ON-DEMAND Webcast

This activity is supported by an educational grant from Diomed, Inc.


Create a Successful Vena Cava Filter Practice

Accredited CD

This activity is supported by an educational grant from Cook Incorporated and has been designed for Interventional Cardiologists, Vascular Surgeons, Fellows and Interventional Cardiovascular Nurses and Technologists.

Achieving Optimal Outcomes in Carotid Stenting: Lessons Learned from Recent Clinical Trials
Complimentary Accredited ON DEMAND Webcast

Topics
1. EVA-3S & Space-Bumps in the road
2. CAPTURE 3500-Lesion morphology & Predictors for Stroke
3. CAPTURE II vs. EXACT 1500-Does open or Closed Cell Stent design really matter?

This activity has been developed for Interventional Cardiologists, Vascular Surgeons, Interventional Radiologists, Neurologists, Interventional Nurses and Technologists with an interest in the diagnosis and treatment of peripheral artery disease.

Anticoagulation Techniques for Peripheral Vascular Interventions

Complimentary Accredited ON DEMAND Webcast

This activity has been developed for Interventional Cardiologists, Vascular Surgeons, Interventional Radiologists, Podiatric Physicians, Endovascular Allied Professionals, Endocrinologists, Wound Care Specialists, Directors of the Wound Care Clinic, and Primary Care Physicians, Pharmacists, Nurses and Technologists.


March 2007 Supplement
On-Demand Webcast
Archived Webcast

About HMP Communications

HMP Communications LLC (HMP) is the authoritative source for comprehensive information and education servicing healthcare professionals. HMP’s products include peer-reviewed and non-peer-reviewed medical journals, national tradeshows and conferences, online programs and customized clinical programs. HMP is a wholly owned subsidiary of HMP Communications Holdings LLC, which also owns the North American Center for Continuing Medical Education (NACCME). NACCME provides a wide array of accredited CME offerings with industry thought leaders participating in roundtable meetings, webcasts, symposia, conferences, seminars, podcasts and satellite programs. Discover more about HMP’s products and services at www.hmpcommunications.com. ©2008 HMP Communications


© 2008 HMP Communications | All Rights Reserved
83 General Warren Blvd, Suite 100 | Malvern, PA 19355 | 800.237.7285